CHAIR
:
SPEAKER
(S):
Robert J. Franco, PhD (SPKNON), Principal, PricewaterhouseCoopers LLP, United States
Kenneth A. Getz,
MBA (SPKSUP), Director of Sponsored Research, Tufts CSDD; Chairman, CISCRP,
Tufts University, United States
Ken is the chairman of CISCRP, and the Director of Sponsored Research / Associate Professor at Tufts CSDD. He is a well-known speaker and author, and serves on a number of for-profit and not-for-profit boards and committees. Ken holds an MBA from the Kellogg School of Management at Northwestern U.
|
Bernard Munos, MBA (SPKNON), Founder, InnoThink, United States
Tomasz Sablinski,
MD (SPKNON), Founder and CEO,
Transparency Life Sciences, United States
Founder and CEO of Transparency Life Sciences, a world 1st open source drug development enterprise. He has been a Managing Director and Head of Celtic Therapeutic Development since 2009. Healthcare career of 30+ years includes clinical practice, basic research, drug development, and investing.
|
Dalvir Gill, PhD (SPKNON), CEO, TransCelerate Biopharma Inc, United States
Andy Lee,
MA (SPKNON), Senior Vice President, Global Clinical Operations,
Genzyme Corporation, A Sanofi Company, United States
Andy heads Global Clinical Operations at Genzyme, and is responsible for all global/regional clinical trials. Andy has over 17 years industry experience with interests in Human Subject Protection, Multiregional Studies, Quality and Compliance and finding more efficient ways to run clinical trials.
|
Description
The landscape for bioinnovation is changing. This session, hosted by the Tufts Center for the Study of Drug Development (CSDD), will examine how companies across the pharma sector are transforming their R&D business models to meet current and future market demands. This senior-level session represents the cross-functional issues that embrace not just R&D, but preclinical, clinical, regulatory, operations, portfolio management and marketing — all aspects of business development. An executive-level panel will lead this interactive session, which will cover topics including:
* What are the greatest market challenges facing the industry today? * In what ways are companies adjusting their R&D business models to meet those challenges? * How has the focus on precision and targeted therapies altered the business model? * What role do partnerships, alliances and collaborations play in the new bioinnovation landscape? * How can government further support innovation within the pharma sector?